Dose-dependent action of atorvastatin in type IIB hyperlipidemia: Preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux

Atherosclerosis

Volumn 163, Issue 2, 2002, Pages 287-296

  Guerin, Maryse ^a   Egger, Pascal ^a   Soudant, Ceéline ^a   Le Goff, Wilfried ^a   Van Tol, Arie ^b   Dupuis, Reynald ^c   Chapman, M John ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c PFIZER INC   (United States)

Author keywords

Cellular cholesterol efflux; Cholesteryl ester transfer protein; Phospholipid transfer protein; Small dense LDL; Triglyceride rich lipoproteins

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; ATORVASTATIN; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERMEDIATE DENSITY LIPOPROTEIN; ISOPROTEIN; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID TRANSFER PROTEIN; STATIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL TRANSPORT; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; FEMALE; HEADACHE; HEPATOMA CELL; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN SYNTHESIS; MALE; MYALGIA; PLASMA; PRIORITY JOURNAL; PROTEIN FUNCTION;

ADULT; AGED; APOLIPOPROTEIN B-100; APOLIPOPROTEINS B; ARTERIOSCLEROSIS; CARRIER PROTEINS; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLYCOPROTEINS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, IDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; LIVER; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PHOSPHOLIPID TRANSFER PROTEINS; PYRROLES;

EID: 0036269506     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(02)00037-0     Document Type: Article

References (30)

1. LDL subfractions and atherogenicity: An hypothesis from the University of Glasgow
2. A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum
3. Lipoprotein of the density 1.006-1.020 in the plasma of patients with type III hyperlipoproteinaemia in the postabsorptive state
4. Two subpopulations of intermediate density lipoprotein and their relationship to plasma triglyceride and cholesterol levels
5. Lipoprotein heterogeneity and apolipoprotein B metabolism
6. Atherogenicity of triglyceride-rich lipoproteins
7. Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits
8. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness
9. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
10. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
11. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: Relative contribution of small, dense LDL to coronary heart disease risk
12. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor
13. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
14. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia
15. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels
16. Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells
17. Action of atorvastatin in combined hyperlipidemia: Preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles
18. A new in vitro method for the simultaneous evaluation of cholesteryl ester exchange and mass transfer between HDL and apoB-containing lipoprotein subspecies. Identification of preferential cholesteryl ester acceptors in human plasma
19. Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma
20. A cell culture system for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum components and efflux, esterification, and transfer
21. Cell cholesterol efflux: Integration of old and new observations provides new insights
22. Short- and long-term effects of atorvastatin, lovastatin and simvastatin on the cellular metabolism of cholesteryl esters and VLDL secretion in rat hepatocytes
23. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study
24. Changes in particle size of high density lipoproteins during incubation with very low density lipoproteins, cholesteryl ester transfer protein and lipoprotein lipase
25. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I
26. The effect of the HMG-CoA reductase inhibitor simvastatin and of cholestyramine on hepatic apolipoprotein mRNA levels in the rat
27. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I
28. Effect of up-regulating individual steps in the reverse cholesterol transport pathway on reverse cholesterol transport in normolipidemic mice
29. Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein
30. Phospholipid transfer protein mediated conversion of high density lipoproteins generates pre beta 1-HDL